Drugs / HY1272
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06218940 | Dec 2024 → Dec 2026 expected | non-small cell lung carcinoma | Newsoara Biopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HY1272 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06218940 ↗ |
| Route | Intravenous | “HY1272 (administered via IV)” NCT06218940 ↗ |